Diffuse Large B Cell Lymphoma Clinical Trials in New York, New York

9 studies are recruiting for diffuse large b cell lymphoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

   Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastom…

   Stage

   Phase 1

   Ages

   0 to 25

   Site

   Memorial Sloan Kettering Cancer Center ( Site 1010), New York, New York

   Locations

   71 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06395103 on ClinicalTrials.gov

2. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

   The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai ( Site 0164), New York, New York

   Locations

   275 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06717347 on ClinicalTrials.gov

3. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Columbia University Medical Center, New York, New York

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov

4. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

5. A Long-term Extension Study of PCI-32765 (Ibrutinib)

   The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been completed according to the parent protocol, are actively rece…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Weill Medical College of Cornell University, New York, New York

   Locations

   175 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT01804686 on ClinicalTrials.gov

6. Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

   This is a pilot study; patients will receive 131-I apamistamab prior to CAR T-cell infusion in order to determine the maximum tolerated dose of 131-I apamistamab is exceeded at 75 mCi, and if so, to assess the safety of a step-down dose of 50 mCi.

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center, New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT04512716 on ClinicalTrials.gov

7. Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

   This phase II trial tests whether mosunetuzumab and/or polatuzumab vedotin helps benefit patients who have received chemotherapy (fludarabine and cyclophosphamide) followed by chimeric antigen receptor (CAR) T-cell therapy (tisagenlecleucel, axicabtagene ciloleucel, or lisocabtagene maraleucel) for…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York

   Locations

   87 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT05633615 on ClinicalTrials.gov

8. ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

   The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the outcomes of participants with undetectable ctDNA in the middle of treatm…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Columbia University, New York, New York

   Run by

   Hua-Jay J Cherng, MD

   See if you can join NCT06693830 on ClinicalTrials.gov

9. A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

   The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test negative for CNS involvement using standard tests. The study will also look at how often CNS relapse h…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06736613 on ClinicalTrials.gov